Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization.

Wang B, Tang Y, Oh Y, Lamb NW, Xia S, Ding Z, Chen B, Suarez MJ, Meng T, Kulkarni V, Eberhart CG, Ensign LM, Stark WJ, Hanes J, Xu Q.

Nanomedicine. 2019 Apr;17:119-123. doi: 10.1016/j.nano.2019.01.001. Epub 2019 Jan 21.

PMID:
30677499
2.

Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.

Luo L, Yang J, Oh Y, Hartsock MJ, Xia S, Kim YC, Ding Z, Meng T, Eberhart CG, Ensign LM, Thorne JE, Stark WJ, Duh EJ, Xu Q, Hanes J.

J Control Release. 2019 Feb 28;296:68-80. doi: 10.1016/j.jconrel.2019.01.018. Epub 2019 Jan 17.

PMID:
30660629
3.

Development of a mucoinert progesterone nanosuspension for safer and more effective prevention of preterm birth.

Hoang T, Zierden H, Date A, Ortiz J, Gumber S, Anders N, He P, Segars J, Hanes J, Mahendroo M, Ensign LM.

J Control Release. 2019 Feb 10;295:74-86. doi: 10.1016/j.jconrel.2018.12.046. Epub 2018 Dec 28.

PMID:
30597245
4.

Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, Narayan J, Zierden H, Betageri K, Musmanno O, Wiegand H, Huang X, Gumber S, Hanes J, Ensign LM.

Biomaterials. 2018 Dec;185:97-105. doi: 10.1016/j.biomaterials.2018.09.005. Epub 2018 Sep 7.

PMID:
30236840
5.

Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.

Hoang T, Date AA, Ortiz JO, Young TW, Bensouda S, Xiao P, Marzinke M, Rohan L, Fuchs EJ, Hendrix C, Gumber S, Villinger F, Cone RA, Hanes J, Ensign LM.

Eur J Pharm Biopharm. 2019 May;138:23-29. doi: 10.1016/j.ejpb.2018.05.030. Epub 2018 May 24.

PMID:
29802984
6.

Pseudomonas aeruginosa pyocyanin production reduced by quorum-sensing inhibiting nanocarriers.

Lu HD, Pearson E, Ristroph KD, Duncan GA, Ensign LM, Suk JS, Hanes J, Prud'homme RK.

Int J Pharm. 2018 Jun 10;544(1):75-82. doi: 10.1016/j.ijpharm.2018.03.058. Epub 2018 Mar 30.

PMID:
29608955
7.

Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.

Hummert P, Parsons TL, Ensign LM, Hoang T, Marzinke MA.

J Pharm Biomed Anal. 2018 Apr 15;152:248-256. doi: 10.1016/j.jpba.2018.02.011. Epub 2018 Feb 8.

8.

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.

Xiao P, Gumber S, Marzinke MA, Date AA, Hoang T, Hanes J, Ensign LM, Wang L, Rohan L, Fuchs EJ, Hendrix C, Villinger F.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01644-17. doi: 10.1128/AAC.01644-17. Print 2018 Jan.

9.

Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.

Schneider CS, Xu Q, Boylan NJ, Chisholm J, Tang BC, Schuster BS, Henning A, Ensign LM, Lee E, Adstamongkonkul P, Simons BW, Wang SS, Gong X, Yu T, Boyle MP, Suk JS, Hanes J.

Sci Adv. 2017 Apr 5;3(4):e1601556. doi: 10.1126/sciadv.1601556. eCollection 2017 Apr.

10.

Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM.

J Control Release. 2017 Oct 10;263:132-138. doi: 10.1016/j.jconrel.2017.01.036. Epub 2017 Jan 31.

11.

Development of Absorbable, Antibiotic-Eluting Sutures for Ophthalmic Surgery.

Kashiwabuchi F, Parikh KS, Omiadze R, Zhang S, Luo L, Patel HV, Xu Q, Ensign LM, Mao HQ, Hanes J, McDonnell PJ.

Transl Vis Sci Technol. 2017 Jan 3;6(1):1. doi: 10.1167/tvst.6.1.1. eCollection 2017 Jan.

12.

North America special issue Part II.

Hanes J, Ensign LM, Kannan R, Suk JS.

J Control Release. 2016 Oct 28;240:1. doi: 10.1016/j.jconrel.2016.09.027. No abstract available.

PMID:
27725132
13.

Mucus-Penetrating Nanosuspensions for Enhanced Delivery of Poorly Soluble Drugs to Mucosal Surfaces.

Yu T, Chisholm J, Choi WJ, Anonuevo A, Pulicare S, Zhong W, Chen M, Fridley C, Lai SK, Ensign LM, Suk JS, Hanes J.

Adv Healthc Mater. 2016 Nov;5(21):2745-2750. doi: 10.1002/adhm.201600599. Epub 2016 Sep 26.

14.

Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.

Henry CE, Wang YY, Yang Q, Hoang T, Chattopadhyay S, Hoen T, Ensign LM, Nunn KL, Schroeder H, McCallen J, Moench T, Cone R, Roffler SR, Lai SK.

Acta Biomater. 2016 Oct 1;43:61-70. doi: 10.1016/j.actbio.2016.07.019. Epub 2016 Jul 14.

15.

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Date AA, Hanes J, Ensign LM.

J Control Release. 2016 Oct 28;240:504-526. doi: 10.1016/j.jconrel.2016.06.016. Epub 2016 Jun 9. Review.

16.

Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo.

Maisel K, Reddy M, Xu Q, Chattopadhyay S, Cone R, Ensign LM, Hanes J.

Nanomedicine (Lond). 2016 Jun;11(11):1337-43. doi: 10.2217/nnm-2016-0047. Epub 2016 May 12.

17.

PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.

Suk JS, Xu Q, Kim N, Hanes J, Ensign LM.

Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51. doi: 10.1016/j.addr.2015.09.012. Epub 2015 Oct 9. Review.

18.

Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.

Xu Q, Ensign LM, Boylan NJ, Schön A, Gong X, Yang JC, Lamb NW, Cai S, Yu T, Freire E, Hanes J.

ACS Nano. 2015 Sep 22;9(9):9217-27. doi: 10.1021/acsnano.5b03876. Epub 2015 Aug 31.

19.

Enema ion compositions for enhancing colorectal drug delivery.

Maisel K, Chattopadhyay S, Moench T, Hendrix C, Cone R, Ensign LM, Hanes J.

J Control Release. 2015 Jul 10;209:280-7. doi: 10.1016/j.jconrel.2015.04.040. Epub 2015 Apr 30.

20.

Particle tracking in drug and gene delivery research: State-of-the-art applications and methods.

Schuster BS, Ensign LM, Allan DB, Suk JS, Hanes J.

Adv Drug Deliv Rev. 2015 Aug 30;91:70-91. doi: 10.1016/j.addr.2015.03.017. Epub 2015 Apr 7. Review.

21.

Modulating Vibrio cholerae quorum-sensing-controlled communication using autoinducer-loaded nanoparticles.

Lu HD, Spiegel AC, Hurley A, Perez LJ, Maisel K, Ensign LM, Hanes J, Bassler BL, Semmelhack MF, Prud'homme RK.

Nano Lett. 2015 Apr 8;15(4):2235-41. doi: 10.1021/acs.nanolett.5b00151. Epub 2015 Mar 3.

22.

Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI).

Yu T, Chan KW, Anonuevo A, Song X, Schuster BS, Chattopadhyay S, Xu Q, Oskolkov N, Patel H, Ensign LM, van Zjil PC, McMahon MT, Hanes J.

Nanomedicine. 2015 Feb;11(2):401-5. doi: 10.1016/j.nano.2014.09.019. Epub 2014 Nov 15.

23.

Hyaluronan in cervical epithelia protects against infection-mediated preterm birth.

Akgul Y, Word RA, Ensign LM, Yamaguchi Y, Lydon J, Hanes J, Mahendroo M.

J Clin Invest. 2014 Dec;124(12):5481-9. doi: 10.1172/JCI78765. Epub 2014 Nov 10.

24.

Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus.

Ensign LM, Lai SK, Wang YY, Yang M, Mert O, Hanes J, Cone R.

Biomacromolecules. 2014 Dec 8;15(12):4403-9. doi: 10.1021/bm501419z. Epub 2014 Nov 11.

25.

Nanoparticle-based drug delivery to the vagina: a review.

Ensign LM, Cone R, Hanes J.

J Control Release. 2014 Sep 28;190:500-14. doi: 10.1016/j.jconrel.2014.04.033. Epub 2014 May 14. Review.

26.

Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth.

Yang M, Yu T, Wang YY, Lai SK, Zeng Q, Miao B, Tang BC, Simons BW, Ensign LM, Liu G, Chan KW, Juang CY, Mert O, Wood J, Fu J, McMahon MT, Wu TC, Hung CF, Hanes J.

Adv Healthc Mater. 2014 Jul;3(7):1044-52. doi: 10.1002/adhm.201300519. Epub 2013 Dec 16.

27.

The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH.

Wang YY, Lai SK, Ensign LM, Zhong W, Cone R, Hanes J.

Biomacromolecules. 2013 Dec 9;14(12):4429-35. doi: 10.1021/bm401356q. Epub 2013 Nov 22.

28.

Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake.

Ensign LM, Hoen TE, Maisel K, Cone RA, Hanes JS.

Biomaterials. 2013 Sep;34(28):6922-9. doi: 10.1016/j.biomaterials.2013.05.039. Epub 2013 Jun 13.

29.

Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues.

Ensign LM, Henning A, Schneider CS, Maisel K, Wang YY, Porosoff MD, Cone R, Hanes J.

Mol Pharm. 2013 Jun 3;10(6):2176-82. doi: 10.1021/mp400087y. Epub 2013 May 23.

30.

Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery.

Ensign LM, Schneider C, Suk JS, Cone R, Hanes J.

Adv Mater. 2012 Jul 24;24(28):3887-94. Review.

31.

Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.

Ensign LM, Tang BC, Wang YY, Tse TA, Hoen T, Cone R, Hanes J.

Sci Transl Med. 2012 Jun 13;4(138):138ra79. doi: 10.1126/scitranslmed.3003453.

32.

Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers.

Ensign LM, Cone R, Hanes J.

Adv Drug Deliv Rev. 2012 May 1;64(6):557-70. doi: 10.1016/j.addr.2011.12.009. Epub 2011 Dec 24. Review.

33.

The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, Hanes J.

Biomaterials. 2009 May;30(13):2591-7. doi: 10.1016/j.biomaterials.2008.12.076. Epub 2009 Jan 26.

Supplemental Content

Loading ...
Support Center